Background: Rapid and early virological responses to peginterferon-alpha and ribavirin are predictive of sustained virological response (SVR) in hepatitis C virus (HCV) infection. We aimed at finding a simple rule to determine the shortest duration of dual therapy for all HCV genotypes, obtained by multiplying time to Initial Viral Response, IVR (first undetectable HCV-RNA) by 4 (Tailored Therapy-4, or TT4). Method: 267 naive HCV-infected patients with compensated liver disease were randomized (2:1) to the TT4 (n = 180) or current standard-of-care (SoC, n = 87) and received peginterferon-alpha plus ribavirin. Patients with HCV-RNA decrease <= 2 log(10) at week 12 or detectable HCV-RNA at week 24 discontinued treatment. Results: Both groups had comparable baseline characteristics, SVR rates were similar in the whole population (60.6% vs. 60.9%) and within each genotype subgroup (G1: 46.6% vs. 55.6%; G2: 90.2% vs. 94.4%; G3: 74.1% vs. 58.3%; G4: 45.8% vs. 33.3%). Relapse rate was higher in G1-TT4 than G1-SoC. Treatment duration in SVR patients was shorter in TT4 compared to SoC, both overall [25 +/- 15 vs. 36 +/- 12.1 weeks], and for subgroups: G1 [35.3 +/- 16.7 vs. 47.3 +/- 2.6 weeks], G2 [18.3 +/- 7.5 vs. 24 +/- 2.8 weeks], G3 [15.2 +/- 8.7 vs. 22.8 +/- 3 weeks] and G4 [26.9 +/- 13 vs. 48 weeks]. Conclusions: In HCV-naive patients, TT4-rule treatment yields similar SVR rates compared to SoC but with shorter treatment duration and remarkable cost reduction. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.

A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: The TT4 randomized trial / Simona, Francioso; Cristiana, Almerighi; Paolo, Forte; Franco, Bandiera; Lorenzo, Nosotti; Raffaella, Lionetti; Taliani, Gloria; Maria Rosaria, Piras; Maria Laura, Ponti; Giustino, Parruti; Francesco Di, Candilo; Silvia, Gentile; Paola, Piccolo; Angela, Salso; Francesca, Riccobelli; Sara, Renzi; Maria Antonella, Longo; Marzia, Montalbano; Salvatore, Zaru; Biliotti, Elisa; Francesco Di, Masi; Francesco, Santopaolo; Mario, Angelico. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - STAMPA. - 46:2(2014), pp. 164-169. [10.1016/j.dld.2013.10.002]

A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: The TT4 randomized trial

TALIANI, Gloria;BILIOTTI, ELISA;
2014

Abstract

Background: Rapid and early virological responses to peginterferon-alpha and ribavirin are predictive of sustained virological response (SVR) in hepatitis C virus (HCV) infection. We aimed at finding a simple rule to determine the shortest duration of dual therapy for all HCV genotypes, obtained by multiplying time to Initial Viral Response, IVR (first undetectable HCV-RNA) by 4 (Tailored Therapy-4, or TT4). Method: 267 naive HCV-infected patients with compensated liver disease were randomized (2:1) to the TT4 (n = 180) or current standard-of-care (SoC, n = 87) and received peginterferon-alpha plus ribavirin. Patients with HCV-RNA decrease <= 2 log(10) at week 12 or detectable HCV-RNA at week 24 discontinued treatment. Results: Both groups had comparable baseline characteristics, SVR rates were similar in the whole population (60.6% vs. 60.9%) and within each genotype subgroup (G1: 46.6% vs. 55.6%; G2: 90.2% vs. 94.4%; G3: 74.1% vs. 58.3%; G4: 45.8% vs. 33.3%). Relapse rate was higher in G1-TT4 than G1-SoC. Treatment duration in SVR patients was shorter in TT4 compared to SoC, both overall [25 +/- 15 vs. 36 +/- 12.1 weeks], and for subgroups: G1 [35.3 +/- 16.7 vs. 47.3 +/- 2.6 weeks], G2 [18.3 +/- 7.5 vs. 24 +/- 2.8 weeks], G3 [15.2 +/- 8.7 vs. 22.8 +/- 3 weeks] and G4 [26.9 +/- 13 vs. 48 weeks]. Conclusions: In HCV-naive patients, TT4-rule treatment yields similar SVR rates compared to SoC but with shorter treatment duration and remarkable cost reduction. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
2014
dual therapy; pegylated interferon; rapid viral response; ribavirin; individualized therapy; hcv treatment; response-guided therapy
01 Pubblicazione su rivista::01a Articolo in rivista
A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: The TT4 randomized trial / Simona, Francioso; Cristiana, Almerighi; Paolo, Forte; Franco, Bandiera; Lorenzo, Nosotti; Raffaella, Lionetti; Taliani, Gloria; Maria Rosaria, Piras; Maria Laura, Ponti; Giustino, Parruti; Francesco Di, Candilo; Silvia, Gentile; Paola, Piccolo; Angela, Salso; Francesca, Riccobelli; Sara, Renzi; Maria Antonella, Longo; Marzia, Montalbano; Salvatore, Zaru; Biliotti, Elisa; Francesco Di, Masi; Francesco, Santopaolo; Mario, Angelico. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - STAMPA. - 46:2(2014), pp. 164-169. [10.1016/j.dld.2013.10.002]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/559645
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact